Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dose-block Randomized, Double-blind, Placebo-controlled, Single and Multiple Dosing, Dose-escalation Phase I Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Characteristics, and Food Effect of HSG4112 After Oral Administration in Healthy and Obese Male Subjects

NCT04732988 is registered in ClinicalTrials.gov with Glaceum as lead sponsor.

NCT NCT04732988
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04732988 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dose-block Randomized, Double-blind, Placebo-controlled, Single and Multiple Dosing, Dose-escalation Phase I Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Characteristics, and Food Effect of HSG4112 After Oral Administration in Healthy and Obese Male Subjects
Lead sponsor
Glaceum
Phase
Phase 1
Overall status
Completed
Start date
August 23, 2018
Completion date
May 24, 2021
Enrollment
90 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

obesity